



## **Clearside Biomedical CEO George Lasezkay to Present at the SHARE™ Series Investor Event on Monday, July 17, 2023**

July 11, 2023

ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer, will present at the SHARE™ Series Monday Management Update for investors on Monday, July 17, 2023, at 11:30 am ET.

This virtual event combines a brief corporate overview with a moderated fireside chat and provides access to individual and institutional investors who will have the opportunity to submit questions during the live session.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: [Events and Presentations](#).

### **About Clearside Biomedical, Inc.**

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, [XIPERE® \(triamcinolone acetonide injectable suspension\)](#) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit [clearsidebio.com](http://clearsidebio.com).

Source: Clearside Biomedical, Inc.

Investor and Media Contacts: Jenny Kobin Remy Bernarda [ir@clearsidebio.com](mailto:ir@clearsidebio.com) (678) 430-8206